so it just speaks to the issue of first of all, the treatment needs to be at a lord to the individual and that if -- tailored -- we need to enter into the prescribing process with an open mind whether in fact this new drug offers any advantage whatsoever to our patients. >> the cost of the treatment will drop by as much as 80%. >> correct. >> and you get the same effect right? >> correct. >> that's really quite dramatic. in fact, it led an editorial writer for the british study, his name is jeffrey lieberman, a researcher in the trial, and he said the claims of superiority were greatly exaggerated, of the new drug. the aggressive marketing of these drugs may have contributed to this enhance perception of effectiveness in the absence of information. so apparently they haven't done their test to show this new drug was an improvement over what existed. there is very little research in this country of com parityive effectiveness. and that is looking at a new drug, comparing it in what we call a head-to-head trial to see whether the drug offers an improvement. when the fda aproves a drug f